Lunsumio

Must be administered by a qualified healthcare professional. Have appropriate medical support available. Risk for CRS. Initiate Lunsumio therapy with step-up dosing schedule and premedicate to reduce the risk for CRS. Ensure adequate hydration and monitor after administration. Monitor for neurologic toxicity (including ICANS), infections prior to and during treatment. Evaluate immediately if CRS (may need hospitalization) or neurologic toxicity (including ICANS) occurs; manage according to guidelines, and provide supportive care; withhold or discontinue based on severity (see full labeling). Active infections: do not initiate. History of recurring or chronic infections (eg, chronic, active Epstein-Barr Virus), underlying conditions that may predispose to infections or those with significant prior immunosuppressive treatment: use cautiously; give antimicrobial prophylaxis as appropriate. Obtain CBCs during treatment. If cytopenias occur, consider prophylactic granulocyte colony-stimulating factor as needed. Bulky tumors or disease (in close proximity to airways or a vital organ): monitor closely during initial therapy. Monitor for signs/symptoms of compression or obstruction due to mass effect secondary to tumor flare; treat if occurs. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 3 months after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 3 months after the last dose).